News

Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder. As part of the deal, Noven will grant Actavis a non-exclusive, royalty-bearing license to

A new distribution center in Singapore and the recent expansion of the company’s facilities in Billerica, Mass., will help PAREXEL more effectively manage clients’ global clinical trial supply

Under the deal, Falk Pharma will assume responsibility and all costs relating to the clinical development and marketing of RhuDex. In return, Medigene will get an upfront payment

Basis of the new vaccine formulation and analysis service are advanced, precise and highly informative analytical techniques. The new service will be centred on XstalBio’s proprietary solid state

The collaboration enables each party to promote innovative new medicine research and development. This is the first time that a compound library partnership of this scale has been

The allowed patent is a formulation patent and covers the DETERx technology platform. As such, the claims cover multiple products in Collegium’s development pipeline. This is the sixth

IBM and NYGC will test a unique Watson prototype designed specifically for genomic research as a tool to help oncologists deliver more personalized care to cancer patients. NYGC

HS-110 is Heat’s first product candidate in a series of its proprietary Immune Pan Antigen Cytotoxic Therapy ("ImPACT") based allogeneic cell lines designed to direct killer T cells

The prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center clinical trial enrolled 230 adult and pediatric patients as young as five years of age, across 31 US sites. For the